Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of pharmaceutical products for the treatment of human diseases. The company offers XERMELO, an orally-delivered small molecule drug candidate for the treatment of carcinoid syndrome diarrhea in combination with somatostatin analog therapy in adults. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that is in Phase 3 clinical trials for the treatment of type 1 and type 2 diabetes; LX2761, which is in Phase 1 clinical development for the treatment of diabetes; and LX9211 that is in Phase 1 clinical development for the treatment of neuropathic pain. The company has strategic collaboration and license agreements with Sanofi; Ipsen Pharma SAS; Bristol-Myers Squibb Company; and Genentech, Inc. Lexicon Pharmaceuticals, Inc. was founded in 1995 and is headquartered in The Woodlands, Texas.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
SymbolNASDAQ:LXRX
CUSIP52887210
Phone281-863-3000
Debt
Debt-to-Equity Ratio-45.80
Current Ratio2.71
Quick Ratio2.68
Price-To-Earnings
Trailing P/E Ratio-8.38
Forward P/E Ratio-7.56
P/E GrowthN/A
Sales & Book Value
Annual Sales$90.33 million
Price / Sales12.23
Cash FlowN/A
Price / CashN/A
Book Value$0.49 per share
Price / Book21.29
Profitability
EPS (Most Recent Fiscal Year)($1.27)
Net Income$-129,050,000.00
Net Margins-137.32%
Return on Equity-369.13%
Return on Assets-37.66%
Miscellaneous
Employees174
Outstanding Shares105,880,000
Market Cap$1.16 billion
Lexicon Pharmaceuticals (NASDAQ:LXRX) Frequently Asked Questions
What is Lexicon Pharmaceuticals' stock symbol?
Lexicon Pharmaceuticals trades on the NASDAQ under the ticker symbol "LXRX."
How were Lexicon Pharmaceuticals' earnings last quarter?
Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) issued its quarterly earnings results on Monday, July, 30th. The biopharmaceutical company reported ($0.33) earnings per share for the quarter, topping the Zacks' consensus estimate of ($0.35) by $0.02. The biopharmaceutical company earned $13.75 million during the quarter, compared to the consensus estimate of $15.88 million. Lexicon Pharmaceuticals had a negative return on equity of 369.13% and a negative net margin of 137.32%. The business's revenue was up 14.1% compared to the same quarter last year. During the same period last year, the business posted ($0.33) EPS. View Lexicon Pharmaceuticals' Earnings History.
When is Lexicon Pharmaceuticals' next earnings date?
What price target have analysts set for LXRX?
5 Wall Street analysts have issued twelve-month price objectives for Lexicon Pharmaceuticals' shares. Their forecasts range from $10.00 to $42.00. On average, they expect Lexicon Pharmaceuticals' share price to reach $24.60 in the next year. This suggests a possible upside of 135.9% from the stock's current price. View Analyst Price Targets for Lexicon Pharmaceuticals.
What is the consensus analysts' recommendation for Lexicon Pharmaceuticals?
5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Lexicon Pharmaceuticals in the last year. There are currently 1 sell rating, 1 hold rating and 3 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Lexicon Pharmaceuticals.
What are Wall Street analysts saying about Lexicon Pharmaceuticals stock?
Here are some recent quotes from research analysts about Lexicon Pharmaceuticals stock:
- 1. According to Zacks Investment Research, "Lexicon Genetics Incorporated is a leader in defining the functions of genes for drug discovery using large-scale knockout mouse technology. Lexicon has invented high-throughput gene trapping technology to discover thousands of genes and expand its OmniBank library of tens of thousands of mouse clones. The Company uses an integrated platform of functional genomic technologies to accelerate large-scale analysis of mammalian gene function for drug discovery. " (8/3/2018)
- 2. Needham & Company LLC analysts commented, "Lexicon presented additional data from sotagliflozin Phase 3 program in at ADA mtg and published full 52wk data from both inTANDEM1 and inTANDEM2 trials. We spoke w/ mgmt for an update. Overall sotagliflozin safety/ efficacy profile is unch and we continue to believe the drug will have a role in T1D treatment. Additional data from dapagliflozin program in T1D were also presented (AstraZeneca/ BMS). Sotagliflozin may have modest benefits as a dual SGLT1/2 inhibitor over single SGLT2 inhibition, but it is still a challenge to compare the drugs across different trials. Maintain HOLD due to slow Xermelo launch and our expectation that Phase 3 T2D next year will help clarify potential overall advantages of sotagliflozin over SGLT2 inhibitors." (6/25/2018)
- 3. Wedbush analysts commented, "Management announced the initiation of its second global Phase 2/3 clinical trial for Plinabulin (for the prevention of chemotherapy-induced neutropenia CIN). Study 106, initiated in China, is enrolling patients who receive TAC (taxotere, doxorubicin and cyclophosphamide) chemotherapy, which often results in severe neutropenia, to demonstrate Plinabulin’s superiority compared with Neulasta, a G-CSF." (11/30/2017)
Who are some of Lexicon Pharmaceuticals' key competitors?
Some companies that are related to Lexicon Pharmaceuticals include Agios Pharmaceuticals (AGIO), HUTCHISON CHINA/S (HCM), Taro Pharmaceutical Industries (TARO), Ultragenyx Pharmaceutical (RARE), GW Pharmaceuticals PLC- (GWPH), Madrigal Pharmaceuticals (MDGL), Endo International (ENDP), Horizon Pharma (HZNP), Intercept Pharmaceuticals (ICPT), Evotec (EVTCY), Array Biopharma (ARRY), Opko Health (OPK), Blueprint Medicines (BPMC), Heron Therapeutics (HRTX) and Akcea Therapeutics (AKCA).
Who are Lexicon Pharmaceuticals' key executives?
Lexicon Pharmaceuticals' management team includes the folowing people:
- Mr. Lonnel Coats, Pres, CEO & Director (Age 53)
- Mr. Jeffrey L. Wade, Exec. VP of Corp. & Admin. Affairs and CFO (Age 53)
- Dr. Pablo Lapuerta, Exec. VP & Chief Medical Officer (Age 55)
- Dr. Praveen Tyle, Exec. VP of R&D (Age 58)
- Mr. Alexander A. Santini, Exec. VP & Chief Commercial Officer (Age 59)
Has Lexicon Pharmaceuticals been receiving favorable news coverage?
News coverage about LXRX stock has been trending somewhat positive this week, Accern reports. Accern identifies negative and positive news coverage by analyzing more than 20 million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. Lexicon Pharmaceuticals earned a daily sentiment score of 0.16 on Accern's scale. They also gave press coverage about the biopharmaceutical company an impact score of 48.82 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company's share price in the next few days. View Recent Headlines for Lexicon Pharmaceuticals.
Who are Lexicon Pharmaceuticals' major shareholders?
Lexicon Pharmaceuticals' stock is owned by many different of institutional and retail investors. Top institutional investors include INVUS, L.P. (55.80%), FMR LLC (14.99%), BlackRock Inc. (4.18%), Sector Gamma AS (0.81%), Pinnacle Associates Ltd. (0.64%) and Marshall Wace LLP (0.61%). Company insiders that own Lexicon Pharmaceuticals stock include Alexander A Santini, James F Tessmer, Jeffrey L Wade, Lonnel Coats, Public Equities LP Invus and Sam L Barker. View Institutional Ownership Trends for Lexicon Pharmaceuticals.
Which institutional investors are selling Lexicon Pharmaceuticals stock?
LXRX stock was sold by a variety of institutional investors in the last quarter, including Pinnacle Associates Ltd., Marshall Wace LLP, State of Wisconsin Investment Board, Virginia Retirement Systems ET AL, Renaissance Technologies LLC, GSA Capital Partners LLP, Cim Investment Mangement Inc. and California Public Employees Retirement System. View Insider Buying and Selling for Lexicon Pharmaceuticals.
Which institutional investors are buying Lexicon Pharmaceuticals stock?
LXRX stock was bought by a variety of institutional investors in the last quarter, including BlackRock Inc., Price Capital Management Inc., FMR LLC, Dynamic Technology Lab Private Ltd, Schwab Charles Investment Management Inc., Tocqueville Asset Management L.P. and Sector Gamma AS. Company insiders that have bought Lexicon Pharmaceuticals stock in the last two years include Alexander A Santini, Jeffrey L Wade, Lonnel Coats, Public Equities LP Invus and Sam L Barker. View Insider Buying and Selling for Lexicon Pharmaceuticals.
How do I buy shares of Lexicon Pharmaceuticals?
Shares of LXRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Lexicon Pharmaceuticals' stock price today?
One share of LXRX stock can currently be purchased for approximately $10.43.
How big of a company is Lexicon Pharmaceuticals?
Lexicon Pharmaceuticals has a market capitalization of $1.16 billion and generates $90.33 million in revenue each year. The biopharmaceutical company earns $-129,050,000.00 in net income (profit) each year or ($1.27) on an earnings per share basis. Lexicon Pharmaceuticals employs 174 workers across the globe.
How can I contact Lexicon Pharmaceuticals?
Lexicon Pharmaceuticals' mailing address is 8800 TECHNOLOGY FOREST PLACE, THE WOODLANDS TX, 77381. The biopharmaceutical company can be reached via phone at 281-863-3000.
MarketBeat Community Rating for Lexicon Pharmaceuticals (NASDAQ LXRX)
MarketBeat's community ratings are surveys of what our community members think about Lexicon Pharmaceuticals and other stocks. Vote "Outperform" if you believe LXRX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe LXRX will underperform the S&P 500 over the long term. You may vote once every thirty days.
